University of Dundee

Lancefield Whole Blood Killing Assay to Evaluate Vaccine Efficacy

Reglinski, Mark

Published in:
Group A Streptococcus

DOI:
[10.1007/978-1-0716-0467-0_25](https://doi.org/10.1007/978-1-0716-0467-0_25)

Publication date:
2020

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):
Reglinski, M. (2020). Lancefield Whole Blood Killing Assay to Evaluate Vaccine Efficacy. In T. Proft, & J. M. S. Loh (Eds.), *Group A Streptococcus: Methods and Protocols* (pp. 317-322). (Methods in Molecular Biology; Vol. 2136). Humana Press. https://doi.org/10.1007/978-1-0716-0467-0_25

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Bactericidal assays: Lancefield whole blood killing assay

Mark Reglinski

Molecular Microbiology, School of Life Sciences, University of Dundee, Dundee, UK.
mreglinski001@dundee.ac.uk.

Abstract

While the Lancefield whole blood killing assay is named for the renowned streptococcal researcher Rebecca Lancefield, the protocol was first described by E.W. Todd in 1927 [1]. Initially, the assay was used to identify novel group A streptococcal (GAS) serotypes through the supplementation of non-immune human blood (often from infants) with type specific antisera prepared in rabbits [2, 3] and to demonstrate the impressive longevity of type specific immunity in patients following invasive GAS infection [4]. The modern assay is routinely used to screen defined GAS mutants [5, 6] or transposon libraries [7] for enhanced susceptibility to opsonophagocytic killing or to screen vaccine antisera [8] or other serological preparations [9] for anti-streptococcal activity.

Keywords: Lancefield assay, whole blood, bacterial killing, opsonophagocytosis, antiserum, mutant screening, multiplication factor

1 Introduction

The fundamental whole blood killing assay protocol has scarcely changed since Todd's first description [1]. Whole blood from healthy human donors is aseptically collected into tubes containing a suitable anti-coagulant and supplemented with 50-100 colony forming units (CFU) of freshly prepared GAS. The reactions are incubated at 37 °C for 3 h under constant agitation and the bacterial density at the

beginning and at the end of the experiment are used to calculate the resulting degree of bacterial growth (denoted the multiplication factor). Multiplication factors calculated under different reaction conditions can be compared to determine, for example, the bactericidal activity of serological preparations or the role of certain genes in GAS resistance to phagocytosis.

Despite several attempts in the mid-20th century, it is clear that the human whole blood used in the assay cannot be reliably substituted with animal blood which remains only weakly bactericidal even when supplemented with human immune factors [10]. The only exception is non-human primate blood which readily kills GAS in the presence of bactericidal human antibodies [10, 3]. The specific differences between human and animal blood that are responsible for this disparity remain unclear however, Stollerman and others have provided evidence for a human specific co-opsonin that is essential for GAS killing [11-13]. Thus, the use of freshly isolated human whole blood remains an absolute requirement for a successful assay.

2 Materials

Prepare all solutions using distilled water and research grade reagents. Ethical approval covering the use of human blood from healthy donors must be obtained prior to conducting this protocol. Blood collections should be performed by a licensed physician or trained phlebotomist.

1. Frozen stocks of GAS strains of interest stored at -80°C in 20% glycerol
2. Columbia blood agar (CBA) plates (see **Note 1**): Prepare 400 ml of Columbia blood agar base in a 500 ml Duran bottle containing an autoclave safe magnetic stir bar according to the manufacturer's instructions and sterilize by autoclaving at 121 °C for 15 minutes. Cool base medium to 50°C and add 5% sterile defibrinated blood stirring continuously. Pour plates immediately and allow to set under the flame or in a laminar flow hood with the lids ajar.

3. Todd-Hewitt broth (THB): Prepare 400 ml of Todd-Hewitt broth in a 500 ml Duran bottle according to the manufacturer's instructions and sterilize by autoclaving at 121 °C for 15 minutes.
4. Phosphate Buffered Saline (PBS): Dissolve 8 g of sodium chloride (NaCl), 0.2 g of potassium chloride (KCl), 1.44 g of dibasic sodium phosphate (Na_2HPO_4) and 0.24 g of monobasic potassium phosphate (KH_2PO_4) in 800 ml H_2O and adjust the pH to 7.4 with HCl as required. Add H_2O to 1L and sterilize by autoclaving at 121 °C for 15 minutes.
5. BD Vacutainer® Safety-Lok™ Blood Collection Sets with Pre-Attached Holder (21-gauge needle)
6. 6 ml BD Vacutainer® blood collection tubes, lithium heparin spray coated (see **Note 2**)
7. Alcohol swabs
8. Tourniquet
9. 2 ml microcentrifuge tubes (see **Note 3**)
10. An end over end rotator capable of securely holding the reaction tubes
11. A 5 % CO_2 static incubator set at 37 °C

3 Method

1. Streak GAS strain of interest onto a CBA plate and culture overnight at 37 °C in 5% CO_2
2. Inoculate a single colony into 5 ml of THB and culture overnight at 37 °C in 5% CO_2 in a static incubator
3. Inoculate 500 μl of the resulting overnight culture 1:10 into fresh, pre-warmed THB and incubate at 37 °C in 5% CO_2 in a static incubator until an A_{600} of 0.15 - 0.2 is reached (see **Note 4**)
4. Dilute culture 1:10,000 in sterile PBS. Plate 30 μl of the diluted GAS onto a CBA plate and culture overnight to determine the starting CFU/reaction

5. Aseptically collected heparinized whole blood from at least three healthy donors (see **Note 5**) and if appropriate supplement with test reagents of interest; for example, rabbit antiserum (see **Note 6**), pooled human immunoglobulin or putative bacteriostatic agents.
6. Inoculate 30 μ l of the diluted GAS into 270 μ l of heparinized blood and incubate for 3 h (see **Note 7**) at 37 °C in 5% CO₂ with constant end over end rotation (see **Note 8**)
7. Place reactions on ice and serially dilute 1:10, 1:100 and 1:1000 in PBS (see **Note 9**)
8. Plate 15 μ l of a neat, 1:10, 1:100 and 1:1000 dilution onto CBA plates and culture overnight to determine the final CFU/reaction
9. Determine the CFU added to the reactions at 0 h and the CFU present in the reactions at 3 h (see **Note 10**) then divide the CFU/reaction (3 h) by the CFU/reaction (0 h) to give the multiplication factor.

4 Notes

1. Pre-poured Columbia blood agar plates are available for purchase from several commercial suppliers. In addition to being more convenient, purchased plates tend to be higher quality and more consistent than plates prepared in house.
2. Rothbard reported a marked reduction in bacteriostatic activity when the anticoagulant heparin was replaced with the calcium-neutralizing agents, potassium and ammonium oxalate or sodium citrate [10]. Defibrination is not recommended due to the risk of decreasing the number of leukocytes below the level required for effective phagocytosis.
3. 1.5 ml microcentrifuge tubes can also be used however it is important to ensure that the blood and streptococci mix effectively while the reactions are agitated.
4. The optical density of 0.15-0.2 is given for guidance and is based on growth of the invasive GAS isolate H305 (National Collection of Type Cultures number: NCTC8198) [14] in freshly prepared THB. The optical density that results in a starting inoculum of 50-100 CFU must be

determined empirically for each strain used. Freshly prepared cultures should be used and not frozen culture stocks.

5. The biggest hurdle that must be overcome when running a whole blood killing assay is inter-donor variation in bacterial multiplication. We and others have found that this effect can be partially ablated through prescreening of donors for ability to support GAS multiplication, or digestion of endogenous immunoglobulin prior to addition of bacteria [15, 16]. However, as discussed above, the bactericidal power possessed by the blood of some individuals cannot be explained satisfactorily by the presence of anti-GAS antibodies. If the difference in bacterial growth in whole blood is subtle between test and control conditions, there may be no alternative but to increase the number of donor blood samples until the null hypothesis can be rejected (or confirmed) with adequate statistical stringency. Three technical replicates of each donor blood sample should be set up to ensure accurate intra-donor multiplication factors are obtained. It is recommended that the assay is set up within 2 h of blood withdrawal.
6. Serum from vaccinated rabbits is most commonly used to assess the efficacy of the humoral immune response to specific antigens [17, 18]. The dilution of antiserum required to promote killing should be determined empirically and will depend upon the concentration and functionality of the test antibodies. Reactions containing pre-immune serum should be included as a control. Reactions can also be supplemented with patient serum or purified human antibodies [9]. Only scant references could be found where mouse antiserum was used in place of rabbit [19, 20].
7. While a 3 h incubation was employed in Rebecca Lancefield's seminal studies [4] and is generally accepted as the standard protocol, published incubation times range from 30 min to 24 h [21, 22, 6]. Thus, the incubation time may have to be optimized for specific applications. Fuller and colleagues noted that after 3 h the surviving streptococci multiply

rapidly to reach densities of “many millions per C.C.” within 24 h. At such densities, subtle difference between immune and non-immune reactions may be difficult to detect [22].

8. Reactions must be agitated to ensure that the leukocytes do not sediment as this will substantially reduce the apparent bactericidal activity of the blood samples. In his original publication, Todd demonstrated that the bactericidal activity of paired blood samples was reduced if incubated under static conditions, and postulated that this resulted from a reduction in contact time between the leukocytes and streptococci [1]. Sealing of tubes and/or use of a 5% CO₂ incubator is essential. If the blood is agitated in an open tube the rapid loss of CO₂ may affect the survival and growth of the GAS isolate [22].
9. Serial 10-fold dilutions in PBS can be prepared in a 96 well plate, allowing three columns of 5 µl dots to be carefully spotted onto a prewarmed blood agar plate using a 1-10 µl multichannel pipette. The dilutions will soak into the agar leaving circles which containing decreasing bacterial densities. One row of these will contain a countable number of colonies following overnight incubation at 37 °C. As undiluted blood will not soak into the agar plate, the lowest dilution that can be assayed in this manner is 1:10.
10. The starting CFU is equivalent to the number of colonies present in 30 µl of the initial GAS dilution (plated during step 4). The final CFU is equivalent to the number of colonies present in the 300 µl reaction following 3 h of incubation (an aliquot of which is plated during step 9).

References

-
1. Todd EW (1927) A Method of Measuring the Increase or Decrease of the Population of Hæmolytic Streptococci in Blood. *Br J Exp Pathol* 8 (1):1-5
 2. Lancefield RC (1957) Differentiation of group A streptococci with a common R antigen into three serological types, with special reference to the bactericidal test. *J Exp Med* 106 (4):525-544
 3. Maxted WR (1956) The indirect bactericidal test as a means of identifying antibody to the M antigen of *Streptococcus pyogenes*. *Br J Exp Pathol* 37 (4):415-422
 4. Lancefield RC (1959) Persistence of type-specific antibodies in man following infection with group A streptococci. *J Exp Med* 110 (2):271-292
 5. Wessels MR, Bronze MS (1994) Critical role of the group A streptococcal capsule in pharyngeal colonization and infection in mice. *P Natl Acad Sci USA* 91 (25):12238-12242

6. Zinkernagel AS, Timmer AM, Pence MA, Locke JB, Buchanan JT, Turner CE, Mishalian I, Sriskandan S, Hanski E, Nizet V (2008) The IL-8 protease SpyCEP/ScpC of group A *Streptococcus* promotes resistance to neutrophil killing. *Cell host & microbe* 4 (2):170-178. doi:10.1016/j.chom.2008.07.002
7. Le Breton Y, Mistry P, Valdes KM, Quigley J, Kumar N, Tettelin H, McIver KS (2013) Genome-wide identification of genes required for fitness of group A *Streptococcus* in human blood. *Infect Immun* 81 (3):862-875. doi:10.1128/iai.00837-12
8. Salehi S, Hohn CM, Penfound TA, Dale JB (2018) Development of an Opsonophagocytic Killing Assay Using HL-60 Cells for Detection of Functional Antibodies against *Streptococcus pyogenes*. *mSphere* 3 (6):e00617-00618. doi:10.1128/mSphere.00617-18
9. Reglinski M, Gierula M, Lynskey NN, Edwards RJ, Sriskandan S (2015) Identification of the *Streptococcus pyogenes* surface antigens recognised by pooled human immunoglobulin. *Sci Rep* 5:15825. doi:10.1038/srep15825srep15825 [pii]
10. Rothbard S (1945) Bacteriostatic Effect of Human Sera on Group a Streptococci : li. Comparative Bacteriostatic Effect of Normal Whole Blood from Different Animal Species in the Presence of Human Convalescent Sera. *J Exp Med* 82 (2):107-118
11. Stollerman GH, Kantor FS, Gordon BD (1958) Accessory plasma factors involved in the bactericidal test for type-specific antibody to group A streptococci. I. A typical behavior of some human and rabbit bloods. *J Exp Med* 108 (4):475-491
12. Stollerman GH, Rytel M, Ortiz J (1963) Accessory plasma factors involved in the bactericidal test for type-specific antibody to group A Streptococci. II. Human plasma cofactor (s) enhancing opsonization of encapsulated organisms. *J Exp Med* 117:1-17
13. Kahlich R, Svec M, Prochazka O (1983) Complex surveillance of streptococcus pyogenes. VI. Relationship between hypersensitivity to zymosan and indicators of immunity against group A streptococci. *J Hyg Epidemiol Microbiol Immunol* 27 (2):219-228
14. Unnikrishnan M, Cohen J, Sriskandan S (2001) Complementation of a speA negative *Streptococcus pyogenes* with speA: effects on virulence and production of streptococcal pyrogenic exotoxin A. *Microb Pathog* 31 (3):109-114. doi:10.1006/mpat.2001.0453
15. Bauer MJ, Georgousakis MM, Vu T, Henningham A, Hofmann A, Rettel M, Hafner LM, Sriprakash KS, McMillan DJ (2012) Evaluation of novel *Streptococcus pyogenes* vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein. *Vaccine* 30 (12):2197-2205. doi:10.1016/j.vaccine.2011.12.115S0264-410X(11)02076-7 [pii]
16. Reglinski M, Lynskey NN, Sriskandan S (2016) Modification of the classical Lancefield assay of group A streptococcal killing to reduce inter-donor variation. *J Microbiol Methods* 124:69-71. doi:10.1016/j.mimet.2016.03.015
17. Courtney HS, Hasty DL, Dale JB (2006) Anti-phagocytic mechanisms of *Streptococcus pyogenes*: binding of fibrinogen to M-related protein. *Mol Microbiol* 59 (3):936-947. doi:10.1111/j.1365-2958.2005.04977.x
18. Lannergard J, Gustafsson MC, Waldemarsson J, Norrby-Teglund A, Stalhammar-Carlemalm M, Lindahl G (2011) The Hypervariable region of *Streptococcus pyogenes* M protein escapes antibody attack by antigenic variation and weak immunogenicity. *Cell Host Microbe* 10 (2):147-157. doi:10.1016/j.chom.2011.06.011
19. Wittner MK, Fox EN (1977) Homologous and heterologous protection of mice with group A streptococcal M protein vaccines. *Infect Immun* 15 (1):104-108
20. Bronze MS, McKinsey DS, Beachey EH, Dale JB (1988) Protective immunity evoked by locally administered group A streptococcal vaccines in mice. *J Immunol* 141 (8):2767-2770
21. Keefer CS, Spink WW (1936) STUDIES OF HEMOLYTIC STREPTOCOCCAL INFECTION I. FACTORS INFLUENCING THE OUTCOME OF ERYSIPELAS. *The Journal of Clinical Investigation* 15 (1):17-19. doi:10.1172/JCI100754
22. Fuller AT, Colebrook L, Maxted WR (1939) Factors which determine the fate of hæmolytic streptococci (group A) in shed blood and in serum. *The Journal of Pathology and Bacteriology* 48 (2):443-464. doi:10.1002/path.1700480217